Innate Pharma has announced the initiation of the Phase 2 dose expansion portion of a clinical trial sponsored by Sanofi. The trial evaluates SAR443579, an investigational trifunctional anti-CD123 NK cell engager, as a monotherapy for treating blood cancers with high unmet medical needs. These cancers include relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia, and high-risk myelodysplasia.
SAR443579 results from a joint research collaboration between Innate Pharma and Sanofi. It has received FDA Fast Track Designation for treating acute myeloid leukemia. Preliminary efficacy and safety data from the dose-escalation phase of the trial were presented at the American Society of Hematology 2023 Annual Meeting.
“The progression of SAR443579 to the Phase 2 expansion phase demonstrates our commitment to bringing this innovative NK cell engager to patients,” said Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma. “Encouraging clinical efficacy has been observed in the dose escalation of Phase 1/2 in R/R AML patients, and we eagerly anticipate the results of the dose expansion.”
Under the terms of the 2016 research collaboration agreement with Sanofi, Innate has been triggered with a €4 million milestone payment.
The ANKET (Antibody-based NK cell Engager Therapeutics) platform, developed by Innate Pharma, enables the creation of multi-specific NK cell engagers for cancer treatment.
Innate Pharma and Sanofi have a research collaboration and license agreement focused on developing innovative multi-specific antibody formats that engage NK cells for tumor cell elimination. Sanofi is responsible for developing, manufacturing, and commercializing products resulting from the collaboration, including SAR443579/IPH6101 and SAR445514/IPH6401. Innate Pharma is eligible for up to €400 million in milestone payments and royalties on net sales.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
